



PRAXIS
PEPTIDE INSTITUTE

SOMATOSTATIN

ADVANCED MECHANISM AND EVIDENCE GUIDE

MULTIRECEPTOR INHIBITORY PEPTIDE SYSTEM AND ANTISECRETORY THERANOSTIC PLATFORM
SST-14 • SST-28 • SSTR1-5 • Gi/o • secretion brake • GH • pancreas • GI • neuroendocrine tumors •
imaging • PRRT

MEMORY KEY: SOMATOSTATIN IS THE BODY'S ENDOCRINE SILENCER: FIVE RECEPTORS REDUCE SECRETORY AMPLITUDE, AND THE CORRECT BRAKE DEPENDS ON THE TISSUE.

Educational monograph • Foundational inhibitory physiology • Established analog therapeutics • Strong receptor imaging and radionuclide targeting

HOW TO USE THIS GUIDE

This guide converts a long-form research narrative into a repeatable learning system. Every future PPI molecule guide can use the same architecture, visual language, evidence labels, and memory devices.

01	IDENTITY What it is - and what it is not
02	PHYSIOLOGY The normal system before the compound
03	MECHANISM Target, pathway, and downstream logic
04	EVIDENCE Cell, animal, and human evidence separated
05	RISK Known concerns, unknowns, and translation limits
06	MONITORING What a legitimate research framework would measure
07	PATIENT CONTEXT Which phenotype might fit the biology
08	RECALL Memory hooks, seven questions, and bottom line

EVIDENCE CODE	CELL = mechanistic ANIMAL = organism-level preclinical HUMAN = clinical translation	CORE DISCIPLINE Mechanism does not equal outcome. Unknown does not equal failed - and unknown does not equal proven.
------------------	---	--

RAPID RECALL

Read this page first. These anchors provide the complete high-level story of Somatostatin; the remaining pages add mechanism, evidence, context, and nuance.

01	IDENTITY Preprosomatostatin produces active SST-14 and SST-28, which signal through five receptor subtypes: SSTR1 through SSTR5.
02	BRAKE Gi/o-coupled SSTR signaling lowers adenylyl cyclase activity, calcium entry, and secretory-vesicle release.
03	NETWORK Somatostatin restrains pituitary, pancreatic, gastrointestinal, exocrine, neuronal, vascular, and tumor-secretory activity.
04	SUBTYPE SSTR2 and SSTR5 often dominate clinical pharmacology, but receptor distribution determines both benefit and adverse effects.
05	ANALOGS Octreotide, lanreotide, and pasireotide extend a minute-long native signal into indication-specific drug profiles.
06	THERANOSTICS SSTR expression can identify tumors on molecular imaging and serve as an address for targeted radionuclide therapy.
07	TRADEOFF The brake that controls pathological excess can also suppress insulin, bile, digestion, thyroid signaling, or normal motility.
08	PRAXIS QUESTION What signal is excessive, which receptor controls it, is that receptor present, and what normal systems share it?

ONE-SENTENCE MEMORY

SOMATOSTATIN IS THE BODY'S ENDOCRINE SILENCER: FIVE RECEPTORS REDUCE SECRETORY AMPLITUDE, AND THE CORRECT BRAKE DEPENDS ON THE TISSUE.

UNDERSTAND THE PEPTIDE

Somatostatin is one of the body's major inhibitory peptide systems.

Where many endocrine peptides say:

RELEASE.

Somatostatin often says:

STOP.

Or more precisely:

SLOW THE SIGNAL DOWN.

That inhibitory role spans multiple organ systems.

Somatostatin can suppress:

- | | |
|-------------------------------------|-------------------------------|
| • growth hormone | • thyroid-stimulating hormone |
| • insulin | • glucagon |
| • gastrin | • secretin |
| • vasoactive intestinal peptide | • motilin |
| • pancreatic polypeptide | • gastrointestinal secretions |
| • several neural signaling pathways | |

It is produced in:

- | | |
|--------------------------|--------------------------|
| • hypothalamus | • pancreas |
| • gastrointestinal tract | • central nervous system |

and works through:

FIVE SOMATOSTATIN RECEPTORS - SSTR1, SSTR2, SSTR3, SSTR4, AND SSTR5.

All five are:

Gi/o-COUPLED G-PROTEIN-COUPLED RECEPTORS.

Their dominant signaling tendency is therefore:

INHIBIT ADENYLYL CYCLASE

cAMP ↓



CALCIUM ENTRY ↓



SECRETORY VESICLE RELEASE ↓

This is why somatostatin is best understood not as:

“THE HORMONE THAT LOWERS GH.”

but as:

A DISTRIBUTED BRAKING SYSTEM FOR ENDOCRINE, EXOCRINE, NEURONAL, AND SECRETORY ACTIVITY.

Modern receptor reviews characterize somatostatin as a broadly inhibitory cyclopeptide acting through five GPCR subtypes with overlapping but distinct tissue distributions and functions.

WHAT IS SOMATOSTATIN?

Somatostatin exists primarily in two biologically active endogenous forms:

SST-14

and:

SST-28.

Both come from the same precursor:

PREPROSOMATOSTATIN.

That precursor is processed into different mature peptides depending on:

- tissue
- enzymatic processing
- cellular context

SST-14

contains:

14 AMINO ACIDS.

It is especially important in:

- hypothalamic
- pancreatic
- neural signaling

SST-28

contains:

28 AMINO ACIDS

and includes the SST-14 sequence at its C-terminal region.

It is especially prominent in:

THE GASTROINTESTINAL TRACT.

Both can activate:

SSTR1-SSTR5.

Again:

ONE PRECURSOR → MULTIPLE ACTIVE PEPTIDES → MULTIPLE RECEPTORS.

Somatostatin biology therefore starts as a:

PEPTIDE-FAMILY SYSTEM

rather than one isolated molecule.

THE CORE SOMATOSTATIN MODEL

Preprosomatostatin



processing



SST-14

or:

SST-28

SSTR1 /
SSTR2 /
SSTR3 /
SSTR4 /
SSTR5

Gi/o

adenylyl
cyclase ↓

cAMP ↓

Ca²⁺
signaling ↓secretory
exocytosis ↓HORMONE / N
EUROTRANS
MITTER /
EXOCRINE
OUTPUT
RESTRAINED

The central concept is:

SOMATOSTATIN IS A BRAKE ON SIGNAL AMPLITUDE.

WHY INHIBITION IS PHYSIOLOGICALLY NECESSARY

Biology requires:

ACTIVATORS

and:

BRAKES.

Without inhibitory control:

a stimulatory pathway can become excessive.

Think about the GH axis.

GHRH says:

RELEASE GH.

Ghrelin says:

RELEASE GH.

Somatostatin says:

NOT NOW.

The actual GH pulse emerges from:

THE BALANCE OF STIMULATORY AND INHIBITORY SIGNALS.

Again:

HORMONE OUTPUT IS NOT JUST ABOUT THE STIMULUS.

It is also about:

HOW MUCH INHIBITION IS PRESENT.

THE GH AXIS BALANCE

GHRH	→	GH ↑
Ghrelin	→	GH ↑
Somatostatin	→	GH ↓

Net output:

PULSATILE GH SECRETION

This is why GH physiology cannot be understood from:

GHRH ALONE.

Somatostatin is an essential counter-signal.

THE SOMATOSTATIN RECEPTOR FAMILY

There are five major human somatostatin receptors:

SSTR1

SSTR2

SSTR3

SSTR4

SSTR5

These are all:

CLASS A / RHODOPSIN-FAMILY GPCRs.

They share broad inhibitory signaling but differ in:

- | | |
|-------------------------|------------------------|
| • tissue distribution | • receptor abundance |
| • ligand affinity | • internalization |
| • desensitization | • downstream signaling |
| • therapeutic relevance | |

Again:

SOMATOSTATIN DOES NOT ACT THROUGH ONE RECEPTOR.

That is clinically important because synthetic analogs do not bind all five receptors equally.

SSTR1

SSTR1 is expressed in:

CNS

- GI tract
- pancreas

and has been associated with:

- inhibitory endocrine signaling
- neuronal regulation
- antiproliferative effects

Its clinical role is less dominant than SSTR2 or SSTR5 in current endocrine pharmacology.

Again:

RECEPTOR EXISTENCE ≠ EQUAL THERAPEUTIC IMPORTANCE.

SSTR2

SSTR2 is one of the most clinically important somatostatin receptors.

It plays major roles in:

- GH suppression
- glucagon suppression
- GI hormone inhibition
- neuroendocrine-tumor biology

It is also highly relevant because many well-differentiated neuroendocrine tumors express:

SSTR2.

That allows the receptor to become:

- a therapeutic target
- an imaging target
- a radiopharmaceutical target

Again:

THE RECEPTOR CAN BECOME BOTH A SIGNALING TARGET AND AN ADDRESS LABEL.

SSTR2 is the most prevalent and therapeutically important receptor in many well-differentiated neuroendocrine neoplasms.

SSTR3

SSTR3 has been associated particularly with:

- inhibitory signaling
- cell-cycle regulation
- apoptosis-related pathways

It is expressed in:

CNS

- pancreas
- GI tissues

but plays a smaller routine therapeutic role than:

SSTR2 / SSTR5.

SSTR4

SSTR4 is expressed prominently in:

- brain
- retina
- selected peripheral tissues

and has been investigated in:

- neurobiology
- pain

- inflammatory signaling

Its current clinical endocrine role is relatively limited.

Again:

NOT EVERY RECEPTOR SUBTYPE HAS THE SAME DISEASE VALUE.

SSTR5

SSTR5 is particularly important in:

- pituitary
- pancreas
- GI tract

It contributes strongly to suppression of:

- growth hormone

ACTH

- insulin

and is a major pharmacological target in:

PITUITARY DISEASE.

Pasireotide, for example, has relatively high affinity for SSTR5 compared with older analogs such as octreotide.

THE RECEPTOR-SUBTYPE PRINCIPLE

Somatostatin



activates all five receptors

But:

- synthetic analog A

may prefer:

SSTR2.

- Synthetic analog B

may prefer:

SSTR5.

Therefore:

two “somatostatin analogs” may have:

VERY DIFFERENT CLINICAL EFFECTS.

Again:

SAME PEPTIDE FAMILY ≠ SAME RECEPTOR PROFILE.

HOW SOMATOSTATIN SIGNALING STOPS SECRETION

The dominant intracellular pathway is inhibitory.

Somatostatin → **SSTR** → **Gi/o** → **adenylyl cyclase inhibited** → **cAMP ↓** → **PKA-related signaling ↓**

Meanwhile:

- voltage-dependent Ca^{2+} channels are inhibited

and:

K⁺ conductance may increase → **cell becomes less excitable** → **Ca²⁺-dependent vesicle fusion ↓** → **HORMONE SECRETION FALLS**

This mechanism has been especially well characterized in pancreatic alpha and beta cells.

THE SECRETORY-BRAKE MODEL

- Hormone-containing vesicle

needs:

- Ca^{2+} SIGNAL

to fuse with the cell membrane.

Somatostatin → **Ca²⁺ entry ↓** → **vesicle fusion ↓** → **hormone release ↓**

Again:

THE PEPTIDE DOES NOT NEED TO DESTROY THE HORMONE.

It can simply:

STOP THE CELL FROM RELEASING IT.

SOMATOSTATIN AND GROWTH HORMONE

Somatostatin was originally identified because of its ability to inhibit:

GROWTH HORMONE RELEASE.

Its original name was:

SOMATOTROPIN RELEASE-INHIBITING FACTOR - SRIF.

At the pituitary:

SSTR2 and SSTR5 are especially important.

Somatostatin → **SSTR2 / SSTR5** → **somatotroph activity ↓** → **GH secretion ↓**

This is the direct physiological counterbalance to:

GHRH + GHRELIN.

THE GH TRIPLE-BALANCE MODEL

GHRH → **STIMULATE**

Ghrelin → **AMPLIFY / STIMULATE**

Somatostatin → **INHIBIT** → **pituitary** → **GH pulse**

Again:

GH PULSATILITY EMERGES FROM A NETWORK, NOT A SINGLE PEPTIDE.

SOMATOSTATIN AND GH PULSATILITY

Somatostatin does not simply hold GH:

PERMANENTLY LOW.

Its release itself varies.

Periods of reduced somatostatin tone can allow:

GH PULSES.

Periods of increased somatostatin tone can produce:

GH TROUGHS.

So:

the inhibitory hormone participates in:

THE RHYTHM.

Again:

INHIBITION CAN CREATE TIMING.

That is a crucial endocrine concept.

THE RELEASE-FROM-INHIBITION PRINCIPLE

Sometimes a hormone pulse occurs not because:

THE STIMULUS BECAME MASSIVE

but because:

THE BRAKE WAS REMOVED.

GHRH may remain present.

Somatostatin falls.



GH pulse emerges.

Again:

DISINHIBITION IS A FORM OF SIGNALING.

SOMATOSTATIN AND TSH

Somatostatin also suppresses:

THYROID-STIMULATING HORMONE - TSH.

This is one reason somatostatin analogs can influence:

THYROID AXIS LABORATORY VALUES.

Octreotide labeling specifically notes suppression of TSH.

Again:

a drug targeting GH-related biology can affect:

OTHER PITUITARY HORMONES.

SOMATOSTATIN AND ACTH

Some receptor subtypes - particularly:

SSTR5

- can suppress:

ACTH.

This became highly important in:

CUSHING DISEASE.

Pasireotide exploits this receptor biology.

Pasireotide is FDA approved for adults with Cushing disease when pituitary surgery is not an option or has not been curative.

Again:

RECEPTOR-SUBTYPE EXPRESSION CAN TURN ONE PEPTIDE SYSTEM INTO MULTIPLE ENDOCRINE THERAPIES.

SOMATOSTATIN AND THE PANCREAS

Pancreatic delta cells produce:

SOMATOSTATIN.

Within the pancreatic islet:

delta cells sit near:

- alpha cells
- beta cells

This allows somatostatin to function as:

A PARACRINE SIGNAL.

That means:

it does not necessarily need to travel far through the bloodstream.

It can act locally inside:

THE ISLET MICROENVIRONMENT.

THE PANCREATIC ISLET MODEL

Beta cell	→	insulin
Alpha cell	→	glucagon
Delta cell	→	somatostatin

Then:

somatostatin restrains:

BOTH ALPHA + BETA CELL SECRETION.

Again:

THE ISLET CONTAINS ITS OWN LOCAL BRAKING SYSTEM.

Human pancreatic studies support important roles for SSTR2 and SSTR5 in suppressing insulin and glucagon secretion.

SOMATOSTATIN AND INSULIN

Somatostatin suppresses:

INSULIN RELEASE.

The logic becomes:

glucose enters



beta cell activated



insulin would rise

But:

somatostatin



SSTR signaling

cAMP / Ca²⁺ signaling
reduced

insulin secretion restrained

Again:

somatostatin does not necessarily mean:

NO INSULIN.

It means:

LESS SECRETORY OUTPUT.

SOMATOSTATIN AND GLUCAGON

Somatostatin also inhibits:

GLUCAGON.

This creates a fascinating metabolic balance because insulin and glucagon normally push glucose physiology in:

OPPOSITE DIRECTIONS.

Somatostatin can suppress:

BOTH.

So its net effect on glucose depends on:

WHICH HORMONE IS MORE IMPORTANT IN THAT MOMENT.**Again:****SAME PEPTIDE CAN LOWER TWO OPPOSING HORMONES SIMULTANEOUSLY.**

THE GLUCOSE-PARADOX MODEL

Somatostatin



insulin ↓

Potential:

- glucose ↑

But:

- glucagon ↓

Potential:

- glucose ↓

Therefore net glucose effect:

CONTEXT DEPENDENT.

This becomes highly important with:

SOMATOSTATIN ANALOG PHARMACOLOGY.

WHY SOMATOSTATIN ANALOGS CAN CAUSE HYPERGLYCEMIA

Some somatostatin analogs suppress:

INSULIN

more strongly than they suppress:

GLUCAGON

in certain receptor contexts.

That can produce:

HYPERGLYCEMIA.

Pasireotide is especially relevant because of its strong:

SSTR5 ACTIVITY

and SSTR5's role in beta-cell insulin secretion.

Again:

RECEPTOR SELECTIVITY CHANGES METABOLIC CONSEQUENCES.

OCTREOTIDE VS PASIREOTIDE - GLUCOSE EXAMPLE

OCTREOTIDE

stronger relative activity at:

SSTR2

PASIREOTIDE

stronger relative activity at:

SSTR5

SSTR5 matters strongly in:

INSULIN SECRETION.

Therefore:

pasireotide tends to have a more significant:

HYPERGLYCEMIA LIABILITY.

Again:

SAME DRUG FAMILY. DIFFERENT RECEPTOR MIX.

SOMATOSTATIN AND THE GASTROINTESTINAL TRACT

Somatostatin is a major:

GI ANTISECRETORY PEPTIDE.

It suppresses release of several GI hormones, including:

- gastrin
- secretin

CCK

VIP

- motilin

GIP

- pancreatic polypeptide

It can also reduce:

- gastric acid secretion
- pancreatic exocrine secretion
- intestinal secretion
- splanchnic blood flow

Again:

SOMATOSTATIN CAN QUIET THE DIGESTIVE SYSTEM AT MULTIPLE LEVELS.

THE GI BRAKE MODEL

Food-related signals → gastrin / secretin / CCK / VIP / motilin → secretion + motility + digestion

Somatostatin → multiple pathways restrained → SECRETORY OUTPUT ↓

This makes somatostatin useful pharmacologically in:

HYPERSECRETORY DISEASES.

SOMATOSTATIN AND GASTRIC ACID

Somatostatin inhibits gastric-acid physiology through several mechanisms.

It can suppress:

- gastrin
- histamine-related signaling
- direct parietal-cell output

So:

somatostatin provides a physiological:

ANTI-ACID BRAKE.

Again:

ACID PHYSIOLOGY IS CONTROLLED BY BOTH STIMULATORY AND INHIBITORY PEPTIDES.

SOMATOSTATIN AND GASTRIN

Gastrin promotes:

GASTRIC ACID SECRETION.

Somatostatin restrains gastrin.

This is particularly important in the stomach, where local D cells produce somatostatin.

Low gastric pH can stimulate:

SOMATOSTATIN RELEASE

which then suppresses:

GASTRIN.

That creates:

NEGATIVE FEEDBACK.

THE ACID-FEEDBACK LOOP

Gastrin ↑ → acid ↑ → gastric pH falls → D-cell somatostatin ↑ → gastrin ↓ → acid output restrained

Again:

THE PRODUCT OF THE SYSTEM ACTIVATES ITS OWN BRAKE.

H. PYLORI AND SOMATOSTATIN PHYSIOLOGY

This feedback loop becomes clinically interesting in:

HELICOBACTER PYLORI.

Certain patterns of H. pylori gastritis can reduce:

D-CELL SOMATOSTATIN SIGNALING

gastrin rises



acid physiology changes.

This demonstrates an important systems concept:

INFLAMMATION CAN ALTER HORMONE CONTROL WITHOUT THE HORMONE ITSELF BEING THE PRIMARY DISEASE.

SOMATOSTATIN AND PANCREATIC EXOCRINE FUNCTION

Somatostatin analogs can suppress:

PANCREATIC EXOCRINE SECRETION.

That can contribute to:

- steatorrhea
- malabsorption
- fat-soluble nutrient issues

with prolonged pharmacological exposure.

The 2024 octreotide labeling specifically added warnings regarding:

STEATORRHEA AND MALABSORPTION OF DIETARY FATS.

Again:

SUPPRESSING A SECRETORY SYSTEM CAN REDUCE PATHOLOGICAL EXCESS - OR CREATE PHYSIOLOGICAL DEFICIENCY.

THE U-SHAPED SECRETORY PRINCIPLE

Too much secretion:

pathology.

Appropriate inhibition:

therapy.

Too much inhibition:

malabsorption / endocrine suppression.

Again:

THE GOAL IS NOT MAXIMAL INHIBITION.

It is:

APPROPRIATE SIGNAL RESTRAINT.

SOMATOSTATIN AND MOTILITY

Somatostatin can influence:

GI MOTILITY.

Synthetic analogs may:

- slow transit
- alter gastric emptying
- modify intestinal movement

This is one reason GI symptoms can appear during treatment.

Again:

A SECRETORY PEPTIDE OFTEN ALSO CHANGES MOTOR PHYSIOLOGY.

SOMATOSTATIN AND GALLBLADDER FUNCTION

Somatostatin analogs can reduce:

GALLBLADDER CONTRACTILITY

and:

BILE SECRETION.

Octreotide labeling specifically reports inhibition of gallbladder contractility and an increased incidence of:

- gallstones
- biliary sludge.

The mechanism makes sense.

CCK normally helps:

CONTRACT THE GALLBLADDER.

Somatostatin analogs suppress:

**CCK / GI secretory
physiology.**



**gallbladder emptying
decreases**



bile stasis



stone risk rises.

Again:

**A DRUG'S ADVERSE EFFECT CAN BE THE DIRECT OPPOSITE OF ANOTHER PEPTIDE'S
PHYSIOLOGICAL JOB.**

SOMATOSTATIN VS CCK

CCK

fat / protein arrive



gallbladder contracts



pancreatic enzymes ↑

SOMATOSTATIN

**secretory / digestive signaling
restrained**



gallbladder activity can fall



pancreatic secretion ↓

Again:

CCK = DIGESTIVE DEPLOYMENT

SOMATOSTATIN = DIGESTIVE RESTRAINT

SOMATOSTATIN VS SECRETIN

SECRETIN

acid enters duodenum



bicarbonate secretion ↑

SOMATOSTATIN

- secretory activity ↓

including GI hormone and exocrine output.

Again:

SECRETIN HELPS ACTIVATE A DIGESTIVE RESPONSE.

SOMATOSTATIN HELPS PREVENT EXCESSIVE RESPONSE.

SOMATOSTATIN VS MOTILIN

MOTILIN

fasting MMC



propulsive motor activity

SOMATOSTATIN

broad inhibitory GI signaling



can suppress motilin secretion and alter motility.

Again:

ONE ORGAN SYSTEM CONTAINS BOTH PROPULSIVE AND INHIBITORY PEPTIDES.

NATIVE SOMATOSTATIN HAS A VERY SHORT HALF-LIFE

This is one of the most important pharmacological limitations.

Native somatostatin has a plasma half-life of approximately:

1-3 MINUTES.

That makes it poorly suited to most chronic therapeutic uses.

So researchers created:

SOMATOSTATIN ANALOGS


with:

- longer half-lives
 - improved stability
- altered receptor selectivity
 - injectable depot formulations

Again:

PEPTIDE ENGINEERING TURNED A MINUTE-LONG SIGNAL INTO A CLINICAL DRUG CLASS.

THE PHARMACOKINETIC-ENGINEERING MODEL



Again:

THE BIOLOGY WAS USEFUL. THE NATIVE PHARMACOKINETICS WERE NOT.

OCTREOTIDE

Octreotide is one of the most important somatostatin analogs.

It is a synthetic:

OCTAPEPTIDE.

Compared with native somatostatin:

it has:

- much longer duration
- strong SSTR2 activity
- clinically useful endocrine and GI effects

FDA-approved Sandostatin injection indications include:

ACROMEGALY

- symptomatic treatment of metastatic CARCINOID TUMORS

watery diarrhea associated with VIPOMAS.

Again:

ONE ANALOG CAN TREAT MULTIPLE DISEASES BECAUSE THE SAME RECEPTOR FAMILY REGULATES MULTIPLE SECRETORY SYSTEMS.

OCTREOTIDE AND ACROMEGALY

Acromegaly usually involves:

EXCESS GH SECRETION

from a pituitary adenoma.

Somatostatin analog: → SSTR2 / SSTR5 → somatotroph secretion ↓ → GH ↓ → IGF-1 ↓

FDA labeling specifically notes that octreotide substantially reduces GH and/or IGF-1 in patients with acromegaly.

Again:

this is the mirror image of:

GHRH / GHRELIN THERAPY.

THE ACROMEGALY MODEL

GHRH / ghrelin pathways:

GH UP

Somatostatin analog:

GH DOWN

Same pituitary cell.

Different receptor direction.

Again:

THE THERAPEUTIC ANSWER DEPENDS ON WHETHER THE SIGNAL IS DEFICIENT OR EXCESSIVE.

OCTREOTIDE AND CARCINOID SYNDROME

Some neuroendocrine tumors release:

- serotonin
- other vasoactive mediators

leading to symptoms such as:

- flushing
- diarrhea

Octreotide can suppress:

HORMONE RELEASE FROM THE TUMOR.

That can substantially improve symptoms.

Again:

TREAT THE SECRETORY OUTPUT EVEN IF THE TUMOR STILL EXISTS.

The FDA labeling emphasizes symptomatic control of flushing and severe diarrhea in metastatic carcinoid tumors.

SYMPTOM CONTROL $\neq$ TUMOR ERADICATION

This is a major evidence distinction.

Tumor secretes hormone → octreotide → hormone secretion ↓ → symptoms improve

But:

that does not automatically mean:

THE TUMOR DISAPPEARED.

The octreotide label specifically notes that older trials were not designed to establish reduction in tumor size or growth rate for those indications.

Again:

SECRETORY CONTROL $\neq$ STRUCTURAL CURE.

OCTREOTIDE AND VIPOMA

VIPoma produces excessive:

VASOACTIVE INTESTINAL PEPTIDE.

This can cause profound:

WATERY DIARRHEA.

Somatostatin analog → VIP secretion ↓ → intestinal secretion ↓ → diarrhea improves

Again:

PEPTIDE ANTAGONISM CAN OCCUR BY SUPPRESSING THE RELEASE OF ANOTHER PEPTIDE.

THE VIPOMA MODEL

Tumor → VIP ↑↑ → intestinal water / electrolyte secretion ↑↑ → severe diarrhea

Octreotide → SSTR signaling → VIP release ↓ → secretory diarrhea ↓

This is one of the clearest examples of:

ANTISECRETORY PEPTIDE PHARMACOLOGY.

LANREOTIDE

Lanreotide is another long-acting somatostatin analog.

Like octreotide:

it has strong affinity for:

SSTR2

with additional activity at other subtypes.

It is used in:

- acromegaly
- selected neuroendocrine tumors

Its development reinforced the concept that:

SSTR2-RICH TUMORS CAN BE CONTROLLED THROUGH RECEPTOR-TARGETED PHARMACOLOGY.

PASIREOTIDE

Pasireotide has a different receptor-binding profile.

It has relatively broad receptor activity but especially strong:

SSTR5 AFFINITY.

That makes it particularly relevant in:

CUSHING DISEASE

because many corticotroph adenomas express:

SSTR5.

FDA records confirm pasireotide's approved use in adults with Cushing disease when surgery is not possible or has failed.

Again:

RECEPTOR EXPRESSION IN THE DISEASE DETERMINES WHICH ANALOG MAKES SENSE.

PASIREOTIDE AND HYPERGLYCEMIA

Pasireotide's SSTR5 activity is also why:

HYPERGLYCEMIA

is a major clinical issue.

SSTR5 is important in:

INSULIN SECRETION.

So:

- pituitary benefit

can come with:

PANCREATIC COST.

Again:

THE SAME RECEPTOR PROFILE THAT IMPROVES ONE ORGAN SYSTEM CAN CREATE AN ADVERSE EFFECT IN ANOTHER.

RECEPTOR SELECTIVITY IS A TRADEOFF

Desired:

SSTR5 on corticotroph tumor



ACTH ↓

But:

SSTR5 on beta cell



insulin ↓



glucose ↑

Again:

SELECTIVITY IS ONLY USEFUL IF THE TARGET RECEPTOR'S DISTRIBUTION FITS THE PATIENT.

SOMATOSTATIN AND NEUROENDOCRINE TUMORS

This may be one of the most sophisticated areas of peptide medicine.

Many well-differentiated neuroendocrine tumors overexpress:

SSTR2.

That receptor can then be exploited for:

FUNCTIONAL SUPPRESSION

IMAGING

RADIONUCLIDE THERAPY

The receptor becomes:

A MOLECULAR ADDRESS.

THE THREE-USE RECEPTOR MODEL

Tumor expresses SSTR2.

Then:

- Use 1 - medication

somatostatin analog



hormone secretion ↓

- Use 2 - imaging

radiolabeled SSTR ligand



tumor becomes visible

- Use 3 - therapy

radioisotope attached to SSTR ligand



radiation delivered to tumor

Again:

ONE RECEPTOR CAN BECOME A DIAGNOSTIC AND THERAPEUTIC PLATFORM.

SOMATOSTATIN-RECEPTOR IMAGING

Radiolabeled somatostatin analogs can bind:

SSTR-RICH TUMORS.

PET tracers such as:

- ⁶⁸Ga-DOTATATE

allow clinicians to visualize:

RECEPTOR EXPRESSION IN VIVO.

This is not just:

ANATOMICAL IMAGING.

It is:

MOLECULAR-PHENOTYPE IMAGING.

Again:

THE SCAN SHOWS WHAT THE TUMOR EXPRESSES, NOT JUST WHERE THE TUMOR IS.

THE RECEPTOR-IMAGING PRINCIPLE

CT:

Where is the mass?

SSTR PET:

Does the mass express:

THE TARGET RECEPTOR?

That information can guide:

THERAPY.

Again:

IMAGING CAN BECOME A FUNCTIONAL BIOMARKER.

PEPTIDE RECEPTOR RADIONUCLIDE THERAPY - PRRT

This is where peptide targeting becomes extremely elegant.

Take a somatostatin-receptor ligand.

Attach a therapeutic radionuclide.

For example:

LUTETIUM-177 DOTATATE.

The peptide-like targeting structure binds:

SSTR2-RICH TUMOR CELLS.

radioactive payload delivered locally



tumor receives radiation.

Again:

PEPTIDE RECEPTOR = DELIVERY ADDRESS.

The somatostatin-receptor field is one of the clearest examples of peptide-receptor targeting being used for both imaging and radionuclide treatment.

THERANOSTICS

This concept is called:

THERANOSTICS.

• Therapy
diagnostics.

The same target is used to:

FIND THE DISEASE

and:

TREAT THE DISEASE.

Somatostatin receptors are one of medicine's best examples.

Again:

RECEPTOR BIOLOGY CAN BECOME A COMPLETE CLINICAL PLATFORM.

SSTR EXPRESSION ≠ ALL NEUROENDOCRINE TUMORS

This distinction matters.

Well-differentiated neuroendocrine tumors often express:

HIGH SSTR2.

Poorly differentiated aggressive tumors may express:

LESS.

Therefore:

a tumor's histologic category does not automatically guarantee:

SSTR TARGETABILITY.

Again:

TUMOR TYPE $\neq$ RECEPTOR PHENOTYPE.

RECEPTOR DENSITY MATTERS

More SSTR2	→	better ligand binding	→	potentially:
<ul style="list-style-type: none">• better imaging• better PRRT targeting				<ul style="list-style-type: none">• better SSA response• Less receptor

less target engagement.

Again:

TARGET PRESENCE IS NOT BINARY.

Density matters.

SOMATOSTATIN AND ANTIPROLIFERATIVE SIGNALING

Somatostatin receptors can also influence:

CELL PROLIFERATION.

Mechanisms include:

- protein tyrosine phosphatases
- PI3K/Akt modulation
- cell-cycle control
- MAPK modulation
- apoptosis-related signaling

These effects vary by receptor subtype and tumor context.

Again:

somatostatin analog therapy may do more than:

SUPPRESS HORMONE SECRETION.

In selected tumors it may also:

SLOW GROWTH.

But the magnitude depends heavily on:

TUMOR BIOLOGY + RECEPTOR EXPRESSION.

SECRETION CONTROL VS ANTIPROLIFERATIVE EFFECT

These must remain separate.

- Hormonal syndrome response
- symptoms ↓
- growth slows
- hormone ↓
- Tumor control
- progression delayed

These are:

DIFFERENT ENDPOINTS.

Again:

LESS FLUSHING DOES NOT AUTOMATICALLY MEAN LESS TUMOR.

SOMATOSTATIN AND INSULINOMA

This is where receptor-specific thinking becomes especially important.

Insulinoma:



insulin excessive



hypoglycemia

Somatostatin analog could theoretically:

SUPPRESS INSULIN.

Sounds perfect.

But:

it can also suppress:

GLUCAGON

and other counter-regulatory signals.

In some patients:

hypoglycemia can paradoxically:

WORSEN.

Again:

SUPPRESSING THE DISEASE HORMONE IS NOT ENOUGH IF YOU ALSO SUPPRESS THE BODY'S DEFENSE AGAINST IT.

THE INSULINOMA PARADOX

Octreotide



insulin ↓

good.

But:

- glucagon ↓

bad during hypoglycemia.

Net effect:

depends on:

RECEPTOR EXPRESSION + PATIENT PHYSIOLOGY.

Again:

TARGETING ONE HORMONE INSIDE A MULTIHORMONE NETWORK CAN PRODUCE SURPRISES.

SOMATOSTATIN AND GLUCAGONOMA

Glucagonoma:



glucagon excess

Somatostatin analog



glucagon secretion ↓

Potential:

symptom improvement.

Again:

this illustrates the broad ability of somatostatin analogs to:

SUPPRESS HYPERSECRETORY ENDOCRINE TUMORS.

SOMATOSTATIN AND ACUTE BLEEDING

Somatostatin and octreotide have also been used in:

VARICEAL BLEEDING

because they reduce:

SPLANCHNIC BLOOD FLOW.

This is a different mechanism from:

HORMONE SUPPRESSION.

Again:

same molecule family.

Different:

PHYSIOLOGICAL TARGET.

The octreotide label notes decreased splanchnic blood flow as part of its pharmacology.

SPLANCHNIC BLOOD FLOW

Splanchnic circulation supplies:

- | | |
|------------|-------------------------------|
| • GI tract | • pancreas |
| • spleen | • liver-related portal system |

Reducing splanchnic blood flow can lower:

PORTAL VENOUS INFLOW.

That is one reason somatostatin analog pharmacology became useful in:

PORTAL-HYPERTENSIVE BLEEDING.

Again:

PEPTIDE PHARMACOLOGY CAN ALTER HEMODYNAMICS WITHOUT BEING A “CARDIOVASCULAR PEPTIDE.”

SOMATOSTATIN AND DIARRHEA

Because somatostatin suppresses:

- secretory hormones
- intestinal secretion
- motility

octreotide can be useful in selected forms of:

SEVERE SECRETORY DIARRHEA.

Examples include:

- VIPoma
- carcinoid syndrome
- some high-output GI states

But:

not every diarrhea phenotype is:

HYPERSECRETORY.

Again:

SAME SYMPTOM $\neq$ SAME MECHANISM.

THE DIARRHEA DIFFERENTIAL

Diarrhea may be:

- | | |
|-----------------|--------------------|
| • secretory | • osmotic |
| • inflammatory | • infectious |
| • malabsorptive | • motility-related |

Somatostatin analog makes the most mechanistic sense when:

EXCESSIVE SECRETION IS A MAJOR NODE.

Again:

TREAT THE PATTERN, NOT THE SYMPTOM NAME.

SOMATOSTATIN AND SHORT BOWEL / HIGH OUTPUT

Somatostatin analogs can reduce:

GI SECRETORY OUTPUT.

That can sometimes be useful in:

- short-bowel syndrome
- high-output fistula / ostomy contexts

But excessive suppression can also:

- reduce absorption-related physiology
- worsen steatorrhea
- impair pancreatic secretion

Again:

REDUCING OUTPUT CAN HELP OR HARM DEPENDING ON WHAT THE GUT STILL NEEDS TO DO.

SOMATOSTATIN AND THE BRAIN

Somatostatin is also an important:

NEUROPEPTIDE.

Somatostatin-containing interneurons are widely distributed in:

- cortex
- hippocampus
- hypothalamus

It modulates:

- neuronal excitability
- neurotransmitter release
- circuit inhibition
- cognition-related networks

Again:

the peptide's identity is broader than:

ENDOCRINE INHIBITION.

SOMATOSTATIN INTERNEURONS

In neuroscience:

SST INTERNEURONS

represent an important class of inhibitory neurons.

These neurons release:

GABA

- somatostatin

and participate in:

- dendritic inhibition
- cortical processing
- network timing

Again:

THE SAME PEPTIDE EXISTS IN ENDOCRINE AND NEURAL INHIBITORY SYSTEMS.

SOMATOSTATIN AND NEURODEGENERATION

Somatostatin signaling has been studied in:

- Alzheimer's disease
- cognitive decline
- amyloid biology

But:

this remains an active research area.

Somatostatin is not an established:

NEURODEGENERATIVE THERAPY.

Again:

PATHWAY INVOLVEMENT $\neq$ CLINICAL INDICATION.

SOMATOSTATIN AND PAIN

SSTR4 in particular has attracted interest in:

- nociception
- inflammatory pain

This raises the possibility of receptor-selective analogs that influence:

PAIN

without producing the broad endocrine suppression of nonselective somatostatin.

Again:

RECEPTOR SELECTIVITY MAY ALLOW NEW FUNCTIONS TO BE SEPARATED FROM OLD ONES.

SOMATOSTATIN RECEPTOR DESENSITIZATION

Like other GPCRs:

SSTRs can be:

- phosphorylated
- internalized
- desensitized

SSTR2 has been particularly well studied.

After agonist exposure:

SSTR2 can be phosphorylated → **β -arrestin recruitment** → **receptor internalization** → **surface receptor density ↓** → **signal attenuates.**

Again:

RECEPTOR EXPOSURE CHANGES FUTURE RECEPTOR RESPONSE.

THE DESENSITIZATION MODEL

Agonist repeatedly binds → **SSTR2 activation** → **receptor phosphorylation** → **internalization** → **less receptor at cell surface** → **response changes**

Again:

CHRONIC SIGNAL $\neq$ REPEATED IDENTICAL ACUTE SIGNAL.

This is important in chronic somatostatin-analog therapy.

SOMATOSTATIN AND TACHYPHYLAXIS

Some patients may experience:

LOSS OF BIOCHEMICAL OR SYMPTOM CONTROL

over time.

Potential contributors include:

- receptor downregulation
- tumor evolution
- disease progression
- receptor internalization
- altered receptor subtype expression

Again:

DRUG FAILURE OVER TIME MAY REFLECT BIOLOGY CHANGING, NOT JUST “TOLERANCE.”

RECEPTOR HETERODIMERIZATION

Somatostatin receptors can also interact with:

- each other
- other GPCRs

through:

DIMERIZATION / HETERODIMERIZATION.

This may alter:

- ligand binding
- internalization
- signaling

Again:

A RECEPTOR MAY NOT FUNCTION AS AN ISOLATED SINGLE UNIT.

This is one reason future analog design may become increasingly sophisticated.

SOMATOSTATIN ANALOGS ARE NOT ALL “THE SAME PEPTIDE”

This needs to be explicit.

Native somatostatin:

broad receptor profile.

Octreotide:

stronger preference for:

SSTR2

with some SSTR5 activity.

Lanreotide:

similar general SSTR2-dominant clinical profile.

Pasireotide:

broader profile with especially strong:

SSTR5.

Again:

RECEPTOR AFFINITY PROFILE = CLINICAL PERSONALITY.

THE ANALOG-SELECTION MODEL

Disease expresses:

mostly SSTR2



SSTR2-preferring analog may fit.

Disease expresses:

important SSTR5



SSTR5-active analog may fit.

But:

pancreatic beta cells also express SSTR5



glucose risk changes.

Again:

THE BEST RECEPTOR FOR THE DISEASE MAY ALSO BE PRESENT IN NORMAL TISSUE.

SOMATOSTATIN AND RECEPTOR TESTING

In neuroendocrine tumors:

SSTR expression can be assessed indirectly through:

RECEPTOR IMAGING.

This creates a powerful personalized-medicine principle:

DO NOT ASSUME THE TARGET IS PRESENT.

Measure it.

Again:

TARGET CONFIRMATION BEFORE TARGETED THERAPY.

THE RECEPTOR-PHENOTYPE PRINCIPLE

Diagnosis:

neuroendocrine tumor.

But:

SSTR PET positive?



target present.

SSTR PET weak / negative?



target may be insufficient.

Again:

DISEASE NAME $\neq$ MOLECULAR TARGET CONFIRMATION.

SOMATOSTATIN AND GALLSTONES

Because chronic somatostatin-analog therapy inhibits:

- gallbladder contraction
- bile secretion

gallstones / sludge become:

MECHANISM-BASED ADVERSE EVENTS.

This is not random toxicity.

It is:

EXCESSIVE PHYSIOLOGICAL BRAKING OF THE BILIARY SYSTEM.

SOMATOSTATIN AND MALABSORPTION

Same principle.

- Pancreatic enzymes ↓
- bile-related physiology altered

intestinal secretion
changed



fat digestion may become
impaired



steatorrhea



fat-soluble nutrient
absorption may decline.

Again:

ANTI-SECRETORY BENEFIT CAN BECOME DIGESTIVE DEFICIENCY.

SOMATOSTATIN AND BRADYCARDIA

Octreotide labeling also includes:

CARDIAC CONDUCTION / HEART-RATE ABNORMALITIES.

Potential effects can include:

- bradycardia
- conduction abnormalities
- rhythm changes

Again:

somatostatin-receptor biology extends beyond:

PITUITARY + GUT.

SOMATOSTATIN AND THYROID FUNCTION

Because somatostatin can suppress:

TSH,

chronic analog therapy may alter:

THYROID FUNCTION.

That means thyroid monitoring may become relevant depending on:

- molecule
- dose
- duration

patient context.

Again:

PITUITARY BRAKING CAN SPILL ACROSS MULTIPLE AXES.

SOMATOSTATIN AND VITAMIN B12

Long-term octreotide therapy can also be associated with:

REDUCED VITAMIN B12 LEVELS

in some patients.

The exact mechanism may involve:

- GI physiology
- absorption
- altered secretory environment

Again:

CHRONIC GI ENDOCRINE MODULATION CAN CREATE NUTRITIONAL CONSEQUENCES.

SOMATOSTATIN AND “ANTI-GROWTH” LANGUAGE

Calling somatostatin:

“ANTI-GROWTH HORMONE”

is too narrow.

Calling it:

“ANTI-GROWTH”

is even worse.

Somatostatin does inhibit:

- GH secretion
- selected proliferative pathways

But its broader physiological identity is:

SIGNAL RESTRAINT.

Again:

INHIBITION IS NOT THE SAME AS BIOLOGICAL DESTRUCTION.

SOMATOSTATIN AND CANCER

Somatostatin analogs can have:

ANTIPROLIFERATIVE EFFECTS

in receptor-positive neuroendocrine tumors.

That does not mean somatostatin is:

A UNIVERSAL ANTICANCER PEPTIDE.

The tumor must have:

THE RELEVANT RECEPTOR BIOLOGY.

Again:

RECEPTOR-POSITIVE DISEASE ≠ ALL CANCER.

SOMATOSTATIN AND PRRT - WHY THIS IS MORE THAN DRUG THERAPY

PRRT is perhaps the most important advanced teaching point.

The somatostatin analog does not need to:

KILL THE TUMOR THROUGH ITS OWN SIGNALING.

It can serve as:

A TARGETING VEHICLE.



Again:

THE PEPTIDE'S ROLE CAN BE DELIVERY, NOT DIRECT THERAPY.

This expands the entire concept of peptide medicine.

PEPTIDE AS SIGNAL VS PEPTIDE AS VEHICLE

Traditional peptide drug:

PEPTIDE → RECEPTOR → BIOLOGICAL SIGNAL

PRRT:

PEPTIDE-LIKE LIGAND → RECEPTOR → TARGETED DELIVERY

These are not the same therapeutic architecture.

Again:

A RECEPTOR LIGAND CAN BECOME A HOMING DEVICE.

SOMATOSTATIN AND DIAGNOSTIC IMAGING - SAME LESSON

Attach imaging radionuclide instead
of therapeutic radionuclide.



same receptor



tumor becomes visible.

Therefore:

SOMATOSTATIN RECEPTOR BIOLOGY ENABLES BOTH DIAGNOSIS AND THERAPY.

This is one of the most sophisticated current applications of peptide-receptor medicine.

THE CORE MECHANISM MAP




• Ca²⁺ influx ↓




• ACTH ↓ depending receptor / context

PANCREAS



GI TRACT



and:

SSTR expression can be used for:



The core concept is:

SOMATOSTATIN IS THE BODY'S DISTRIBUTED ANTISECRETORY BRAKE - AND MODERN MEDICINE HAS TURNED THAT BRAKE INTO A RECEPTOR-SELECTIVE DRUG SYSTEM, A TUMOR-IMAGING PLATFORM, AND A TARGETED RADIOTHERAPY DELIVERY SYSTEM.

WHAT THIS MECHANISM MAY SUGGEST

Somatostatin biology is highly relevant to:

- | | |
|--|--|
| <ul style="list-style-type: none"> • GH excess • Cushing disease • carcinoid syndrome • glucagonoma • secretory diarrhea • pancreatic secretion • pituitary biology | <ul style="list-style-type: none"> • acromegaly • neuroendocrine tumors • VIPoma • insulinoma physiology • portal / splanchnic hemodynamics • GI hormone regulation • receptor-targeted imaging |
| <ul style="list-style-type: none"> • peptide receptor radionuclide therapy • neurobiology | <ul style="list-style-type: none"> • SSTR-selective drug development • pain research |

Its strongest clinical identity is:

BROAD ANTISECRETORY CONTROL THROUGH SSTRs, WITH ESPECIALLY IMPORTANT CLINICAL USE OF SSTR2 AND SSTR5.

WHAT THIS MECHANISM DOES NOT PROVE

Somatostatin biology does not prove that:

- | | |
|---|--|
| <ul style="list-style-type: none"> • inhibition is always beneficial • lowering GH is useful in every patient • lowering glucagon is useful in every patient • all somatostatin receptors do the same thing • octreotide and pasireotide have the same glucose effects • SSTR expression guarantees clinical response • reduced hormone secretion proves tumor eradication | <ul style="list-style-type: none"> • more somatostatin is always safer • lowering insulin is useful in every patient • suppressing GI secretion always improves digestion • all somatostatin analogs are interchangeable • all neuroendocrine tumors express SSTR2 • symptom improvement proves tumor shrinkage • receptor positivity alone determines PRRT success |
| <ul style="list-style-type: none"> • every diarrhea syndrome should respond to octreotide • gallstones are unrelated to receptor biology • anti-proliferative signaling makes somatostatin a universal cancer therapy | <ul style="list-style-type: none"> • every insulinoma improves with somatostatin analog therapy • hyperglycemia is random toxicity |

receptor expression outside endocrine tissue proves a therapeutic indication

- a longer-acting analog is always better than native physiology
- maximal receptor activation is the therapeutic goal

Again:

INHIBITION MUST BE MATCHED TO THE PATHOLOGICAL EXCESS.

THE EVIDENCE, POTENTIAL APPLICATIONS, AND LIMITATIONS

ENDOGENOUS SOMATOSTATIN PHYSIOLOGY

EXTREMELY STRONG

SST-14 and SST-28 are well-established endogenous inhibitory peptides acting through:

SSTR1-SSTR5.

SSTR SIGNALING

EXTREMELY STRONG

All five receptors are Gi/o-coupled GPCRs that generally:

- reduce cAMP
- inhibit calcium entry

suppress secretion.

GH SUPPRESSION

EXTREMELY STRONG

SSTR2 and SSTR5 are major mediators of:

GH INHIBITION.

ACROMEGALY

VERY STRONG HUMAN CLINICAL EVIDENCE

Octreotide and other somatostatin analogs are established therapies for reducing:

GH

IGF-1

in selected patients with acromegaly.

CUSHING DISEASE

STRONG HUMAN CLINICAL EVIDENCE FOR PASIREOTIDE

Pasireotide is FDA approved for adults with Cushing disease when surgery is not an option or has not been curative.

CARCINOID SYNDROME / VIPOMA

STRONG HUMAN CLINICAL EVIDENCE FOR SYMPTOM CONTROL

Octreotide is FDA approved for symptomatic management of:

- metastatic carcinoid syndrome

VIPoma-associated watery diarrhea.

NEUROENDOCRINE-TUMOR RECEPTOR TARGETING

VERY STRONG

SSTR2 expression is a major therapeutic and imaging target in:

WELL-DIFFERENTIATED NENs.

ANTIPROLIFERATIVE EFFECTS

MEANINGFUL AND DISEASE SPECIFIC

Somatostatin-receptor signaling can influence:

- proliferation

MAPK

- PI3K/Akt

phosphatase pathways.

But:

THE MAGNITUDE DEPENDS ON TUMOR TYPE + RECEPTOR PHENOTYPE.

NEURAL / PAIN / EXTRAPITUITARY APPLICATIONS

BIOLOGICALLY INTERESTING - LESS CLINICALLY ESTABLISHED

These remain important research domains.

- Research

ACROMEGALY

This is one of the cleanest mechanism-to-disease matches.

Disease:

TOO MUCH GH.

Somatostatin receptor agonism:



GH secretion ↓



IGF-1 ↓

Again:

EXCESS SIGNAL → ACTIVATE THE BRAKE.

CUSHING DISEASE

Corticotroph tumor



ACTH ↑

If tumor expresses:

SSTR5

then:

pasireotide



ACTH ↓

Again:**RECEPTOR PHENOTYPE GUIDES THERAPY.****NEUROENDOCRINE TUMORS**

The key question is not only:

WHAT TUMOR IS THIS?**But:****WHAT RECEPTORS DOES IT EXPRESS?**

That determines:

- hormonal control
- imaging
- therapeutic targeting

Again:**HISTOLOGY + RECEPTOR PHENOTYPE.****SECRETORY DIARRHEA**

Somatostatin analogs make sense when:

EXCESS PEPTIDE / SECRETORY DRIVE

is causing:

FLUID LOSS.**But:**

infectious or inflammatory diarrhea may require:

COMPLETELY DIFFERENT THINKING.**Again:****DIARRHEA IS A SYMPTOM, NOT A MECHANISM.****GLUCOSE**

This is a major area where receptor selectivity matters.

Suppression of:

- insulin

and:

- glucagon

can produce different net glucose outcomes.

Future analog development may attempt to:

SEPARATE PITUITARY / TUMOR BENEFIT FROM PANCREATIC METABOLIC COST.

Again:

SELECTIVITY IS THE FUTURE.

SSTR-TARGETED THERANOSTICS

This is one of the most advanced areas of peptide medicine.

The receptor can be:

- imaged
- measured indirectly
- therapeutically targeted

The future likely includes:

- better radionuclides
- improved ligands
- receptor-antagonist tracers
- personalized dosimetry
- receptor-subtype-specific targeting

Again:

THE RECEPTOR BECOMES A MAP.

WHAT WE KNOW

Somatostatin is an endogenous inhibitory peptide system existing predominantly as SST-14 and SST-28.

Both mature peptides activate five somatostatin receptors - SSTR1 through SSTR5.

These receptors are class-A GPCRs coupled primarily to Gi/o proteins.

Their canonical signaling reduces adenylyl cyclase activity, lowers intracellular cAMP, alters calcium and potassium-channel activity, and suppresses secretory exocytosis.

This makes somatostatin one of the body's major endocrine and exocrine inhibitory systems.

At the pituitary, somatostatin is a major physiological brake on GH secretion, especially through SSTR2 and SSTR5.

This creates the inhibitory counterpart to GHRH and ghrelin.

GH physiology therefore emerges from the balance between stimulation and restraint rather than from GHRH alone.

Somatostatin is also produced by pancreatic delta cells and locally suppresses both insulin and glucagon secretion.

That is why somatostatin analogs can alter glucose in complex ways.

Suppressing insulin can raise glucose.

Suppressing glucagon can lower glucose.

The net effect depends on receptor selectivity, metabolic state, and which pancreatic signal is suppressed most strongly.

Somatostatin also suppresses numerous GI hormones and exocrine secretions, including gastrin, secretin, VIP, motilin, and pancreatic secretory activity.

This broad antisecretory physiology explains much of the clinical utility of somatostatin analogs in hypersecretory disease.

Native somatostatin itself is difficult to use chronically because its plasma half-life is only approximately one to three minutes.

Synthetic analogs such as octreotide, lanreotide, and pasireotide were therefore developed to create longer-lasting and more receptor-selective pharmacology.

Octreotide is FDA approved for acromegaly and for symptomatic treatment of metastatic carcinoid tumors and VIPomas.

Pasireotide provides a different receptor profile with strong SSTR5 activity and is FDA approved for selected adults with Cushing disease.

These analogs illustrate that the term “somatostatin analog” does not define one pharmacology.

Receptor-subtype affinity matters.

Octreotide's SSTR2-dominant profile differs meaningfully from pasireotide's stronger SSTR5 activity.

That difference affects both therapeutic efficacy and adverse effects such as hyperglycemia.

Somatostatin-receptor biology has also become foundational to modern neuroendocrine-tumor medicine.

Well-differentiated neuroendocrine tumors frequently overexpress SSTR2.

That receptor can be targeted with medications to suppress hormone secretion, with radiolabeled ligands to visualize tumors, and with therapeutic radionuclides to deliver radiation selectively.

This is one of medicine's clearest examples of peptide-receptor theranostics.

The receptor is not merely a signaling molecule.

It becomes a molecular address.

WHAT WE THINK MAY BE HAPPENING

Somatostatin may be best understood as:

THE BODY'S ENDOCRINE SILENCER.

Imagine a meal.

Multiple signals begin rising.

Gastrin.

CCK.

Secretin.

Insulin.

Glucagon.

Motilin-related motor programs change.

Pancreatic secretion changes.

Acid changes.

The system needs:

ACTIVATION.

But if every signal were allowed to continue unchecked:

the digestive response would overshoot.

So somatostatin appears.

And says:

ENOUGH.

Now imagine the pituitary.

GHRH rises.

Ghrelin rises.

GH surges.

Then the system needs:

A TROUGH.

Somatostatin helps create it.

Again:

INHIBITION CREATES RHYTHM.

Now imagine a neuroendocrine tumor.

The tumor is secreting:

TOO MUCH HORMONE.

The disease is not necessarily:

- “too much tumor mass.”

The immediate problem may be:

TOO MUCH SECRETORY OUTPUT.

Somatostatin analog → receptor activated → secretory machinery quiets → symptoms improve.

Then medicine takes the concept even further.

The tumor displays:

SSTR2.

So instead of merely activating that receptor:

we attach:

A RADIOACTIVE IMAGING MOLECULE.

Now the tumor lights up.

Then we attach:

A THERAPEUTIC RADIONUCLIDE.

Now the same receptor helps deliver:

RADIATION DIRECTLY TO THE TUMOR.

That is a profound evolution of peptide medicine.

First:

PEPTIDE AS HORMONE.

Then:

PEPTIDE ANALOG AS DRUG.

Then:

RECEPTOR LIGAND AS IMAGING AGENT.

Then:

RECEPTOR LIGAND AS TARGETED DELIVERY VEHICLE.

Somatostatin may therefore be one of the best examples in the entire guide series of how understanding:

ONE ENDOGENOUS PEPTIDE SYSTEM

can eventually produce:

AN ENTIRE MEDICAL TECHNOLOGY PLATFORM.

WHAT REMAINS CONTEXT-DEPENDENT

Important questions include:

How does SST-14 physiology differ functionally from SST-28 in humans?

Which tissues preferentially release SST-14 versus SST-28?

How much does local paracrine somatostatin matter compared with circulating somatostatin?

How important is somatostatin pulse timing in human GH physiology?

Does GH pulsatility depend more on somatostatin withdrawal or GHRH rise?

How does ghrelin interact with somatostatin tone?

How does sleep alter somatostatin secretion?

How does obesity alter somatostatin-mediated GH suppression?

Does aging increase hypothalamic somatostatin tone?

Does this contribute materially to somatopause?

Can receptor-specific antagonism restore physiological GH without excessive stimulation?

How much do SSTR1-5 differ in signaling bias?

Which intracellular pathways matter beyond Gi/o?

How important are protein tyrosine phosphatases to antiproliferative effects?

Which SSTRs most strongly alter PI3K/Akt?

Which most strongly alter MAPK?

How much receptor dimerization occurs in human tissues?

Does SSTR2/SSTR5 heterodimerization alter drug response?

Can receptor dimer patterns predict clinical efficacy?

How much SSTR2 internalization contributes to long-term analog resistance?

Does SSTR5 desensitize differently?

Can ligand-biased analogs reduce desensitization?

Can receptor antagonists outperform agonists for imaging because they recognize more receptor conformations?

Which SSTR subtype is optimal for each neuroendocrine-tumor phenotype?

Can receptor-expression imaging predict octreotide response quantitatively?

What receptor-density threshold predicts PRRT benefit?

How much tumor heterogeneity exists within a single patient?

Can one metastasis be strongly SSTR2-positive while another is weakly positive?

How should treatment change when receptor phenotype evolves?

Can repeated PRRT select for SSTR-low tumor clones?

How should SSTR PET be integrated with FDG PET in aggressive disease?

Can receptor phenotype predict tumor differentiation?

Which patients benefit most from octreotide versus lanreotide?

Which patients benefit most from pasireotide?

Can SSTR5-selective therapy suppress ACTH while sparing pancreatic insulin secretion?

Can tissue-selective analogs reduce hyperglycemia?

Can SSTR2-selective analogs improve neuroendocrine-tumor control without excessive biliary effects?

Why do some acromegaly patients respond poorly despite measurable receptor expression?

Do SSTR2:SSTR5 ratios predict acromegaly response?

How much does tumor granulation pattern matter?

Can receptor expression change after therapy?

Can somatostatin analogs shrink pituitary adenomas independently of hormone suppression?

What predicts tumor shrinkage?

Which carcinoid-syndrome patients need higher receptor exposure?

What causes loss of symptom control over time?

Does tachyphylaxis reflect receptor internalization or tumor progression?

Can drug holidays restore receptor responsiveness?

Does prolonged somatostatin analog therapy alter normal endocrine-cell populations?

How much pancreatic exocrine suppression occurs at different doses?

Which patients are most vulnerable to steatorrhea?

Should fecal elastase or fat-soluble vitamins be monitored in long-term therapy?

Can pancreatic enzyme replacement offset analog-induced malabsorption?

What predicts gallstone formation?

Can gallbladder surveillance improve outcomes?

How much does treatment duration matter?

Can CCK physiology be preserved while maintaining tumor control?

Why is pasireotide-associated hyperglycemia so variable among patients?

Does baseline beta-cell reserve predict risk?

Can incretin-based drugs counteract pasireotide-associated hyperglycemia?

How should insulin and glucagon suppression be modeled dynamically?

Can somatostatin antagonism have therapeutic value in diabetes?

Could selective alpha-cell or beta-cell SSTR modulation improve glucose control?
Can SSTR antagonists increase insulin without excessive glucagon?
How important is pancreatic paracrine somatostatin in type 1 diabetes?
Does delta-cell remodeling contribute to diabetes progression?
How does somatostatin affect glucagon counter-regulation during hypoglycemia?
Can SSTR2 antagonism improve impaired glucagon responses?
What role does somatostatin play in gastric acid disorders?
How much does H. pylori alter D-cell somatostatin?
Can restoring local somatostatin normalize gastrin physiology?
Does chronic PPI therapy alter somatostatin-gastrin feedback?
How much does somatostatin contribute to gastric-motility disorders?
Can selective SSTR4 agonists become analgesic drugs?
What role does somatostatin play in neuroinflammation?
Are SST interneuron changes causal in Alzheimer's disease or secondary?
Can CNS-targeted SSTR modulation improve cognition?
Can peptide analogs cross the blood-brain barrier sufficiently?
Can receptor-selective agonists separate neural effects from endocrine suppression?
How far can SSTR-targeted theranostics expand beyond neuroendocrine tumors?
Which non-NET cancers express clinically useful SSTR levels?
Can SSTR targeting deliver non-radioactive cytotoxic payloads?
Can SSTR ligands deliver nanoparticles or gene therapies?
Can personalized dosimetry improve PRRT therapeutic index?
Will alpha-emitting radionuclides outperform beta emitters in selected disease?
Can tandem radionuclide strategies improve receptor-positive tumor control?
Can receptor imaging be used to monitor treatment-induced molecular evolution?

Again:

these are the questions needed to move from:

GENERAL INHIBITORY PEPTIDE

to:

PRECISION SOMATOSTATIN-RECEPTOR PHARMACOLOGY AND THERANOSTICS.

THE PRAXIS LENS

DO NOT BEGIN WITH SOMATOSTATIN

Begin with:

WHAT SIGNAL IS EXCESSIVE, WHICH SOMATOSTATIN RECEPTOR CONTROLS THAT SIGNAL, AND WHAT NORMAL PHYSIOLOGY WILL ALSO BE SUPPRESSED IF WE ACTIVATE THAT RECEPTOR?

Then:

PHYSIOLOGY

PATTERN



MECHANISM



EVIDENCE



RISK



MONITORING



DECISION

PHYSIOLOGY

Normal somatostatin physiology requires:

- appropriate SST-14 / SST-28 release
- local paracrine control
- appropriate pancreatic alpha / beta-cell restraint
- preserved receptor responsiveness
- intact SSSTR signaling
- appropriate pituitary inhibition
- balanced GI secretory control

Its central identity is:

NEGATIVE REGULATION OF SECRETORY SIGNALING.

PATTERN

What is actually excessive?

GH?

ACTH?

VIP?

serotonin-related tumor secretion?

insulin?

glucagon?

gastrin?

intestinal secretion?

portal blood flow?

Again:

“SOMATOSTATIN ANALOG” IS NOT A DIAGNOSIS.

MECHANISM

Which receptor matters?

SSTR2?

SSTR5?

Both?

Does the target tissue express it?

And what normal tissue expresses the same receptor?

Example:

SSTR5 on corticotroph tumor



ACTH suppression desirable.

But:

SSTR5 on pancreatic beta cell



insulin suppression undesirable.

Again:

TARGET BENEFIT + OFF-TARGET PHYSIOLOGY ARE OFTEN THE SAME RECEPTOR IN DIFFERENT TISSUES.

EVIDENCE

Ask:

WHAT CLAIM ARE WE MAKING?

Somatostatin inhibits GH?

EXTREMELY STRONG.

SSTR1-5 exist and signal predominantly through Gi/o?

EXTREMELY STRONG.

Octreotide reduces GH / IGF-1 in acromegaly?

VERY STRONG.

Octreotide controls carcinoid / VIPoma secretory symptoms?

STRONG HUMAN CLINICAL EVIDENCE.

Pasireotide can treat selected Cushing disease?

YES.

SSTR expression enables receptor-targeted tumor imaging and therapy?

VERY STRONG.

Does symptom suppression prove tumor eradication?

NO.

Again:

KEEP THE ENDPOINT AT THE EVIDENCE LEVEL.

RISK

The central risk is:

EXCESSIVE INHIBITION OF NORMAL PHYSIOLOGY.

Potential consequences include:

- hyperglycemia
- hypoglycemia in selected contexts
- gallstones
- biliary sludge
- steatorrhea
- fat malabsorption
- GI symptoms
- bradycardia / conduction abnormalities
- thyroid-axis suppression
- nutritional consequences
- suppression of needed counter-regulatory hormones

Again:

THE PHARMACOLOGY WORKS BY SUPPRESSION - SO OVER-SUPPRESSION IS THE MECHANISTIC RISK.

MONITORING

Monitoring should follow:

THE RECEPTOR + TARGET ORGAN + SUPPRESSED PHYSIOLOGY.

ACROMEGALY

GH

IGF-1

- symptoms
- tumor imaging where appropriate

CUSHING DISEASE

- cortisol

ACTH

- glucose
- clinical phenotype

NEUROENDOCRINE TUMORS

- syndrome-specific hormones
- symptoms
- imaging
- receptor imaging
- tumor progression

GLYCEMIA

- fasting glucose
- A1c
- CGM where useful
- insulin / medication requirements

BILIARY

- biliary symptoms
- gallbladder imaging when clinically indicated

DIGESTIVE

- steatorrhea
- weight
- pancreatic exocrine function if suspected
- stool changes
- fat-soluble nutrient status where appropriate

CARDIAC

- heart rate
- conduction / ECG where clinically relevant

THYROID**TSH**

- free T4 where appropriate

Again:

MONITOR WHAT THE DRUG IS SUPPRESSING.

THE PRAXIS 5**MECHANISM**

Somatostatin's defining pathway is:

SST-14 / SST-28 → SSTR1-5 → Gi/o → cAMP ↓ + Ca²⁺ ↓ → SECRETORY OUTPUT ↓.

Its central identity is:

MULTISYSTEM ANTISECRETORY BRAKING.

EVIDENCE

Endogenous physiology:

EXTREMELY STRONG.

Receptor biology:

EXTREMELY STRONG.

Acromegaly:

VERY STRONG.

Carcinoid / VIPoma symptom control:

STRONG.

Cushing disease with pasireotide:

STRONG.

NET receptor imaging / targeted therapy:

VERY STRONG.

Neural / pain / other emerging applications:

EARLIER / CONTEXT DEPENDENT.

RISK

The biggest conceptual mistake is:

ASSUMING INHIBITION IS INHERENTLY PROTECTIVE.

Sometimes the body needs:

- | | |
|---------------|----------------------|
| • insulin | • glucagon |
| • bile | • pancreatic enzymes |
| • GI motility | |

TSH

So:

THE SAME BRAKE THAT TREATS EXCESS CAN CREATE DEFICIENCY WHEN PUSHED TOO FAR.

MONITORING

Monitor:

TARGET HORMONE + TARGET DISEASE + NORMAL SYSTEMS SHARING THE RECEPTOR.

Again:

if GH decreases but:

- glucose worsens badly,

the treatment produced:

TARGET SUCCESS + SYSTEM COST.

Both matter.

PATIENT CONTEXT

A patient with:

ACROMEGALY

needs:

MORE INHIBITION OF GH.

A patient with:

GH DEFICIENCY

needs the opposite.

A patient with:

VIOMA SECRETORY DIARRHEA

may benefit from powerful antisecretory signaling.

A patient with:

PANCREATIC EXOCRINE INSUFFICIENCY

may be harmed by more suppression.

A patient with:

SSTR2-POSITIVE NET

may be highly targetable.

A patient with:

SSTR-LOW POORLY DIFFERENTIATED TUMOR

may not be.

Same pathway.

Different:

VALUE + RISK.

SEVEN QUESTIONS TO ASK BEFORE TARGETING SOMATOSTATIN

1. WHAT SIGNAL IS ACTUALLY EXCESSIVE?

GH?

ACTH?

insulin?

glucagon?

VIP?

serotonin-related secretion?

GI fluid secretion?

2. WHICH SSTR SUBTYPE CONTROLS THAT SIGNAL?

SSTR2?

SSTR5?

Another subtype?

3. DOES THE DISEASE TISSUE ACTUALLY EXPRESS THE TARGET RECEPTOR?

Especially in:

NEUROENDOCRINE TUMORS.

4. WHAT NORMAL TISSUES EXPRESS THE SAME RECEPTOR?

This predicts:

OFF-TARGET PHYSIOLOGY.

5. WHAT IS THE THERAPEUTIC ENDPOINT?

Hormone suppression?

Symptom control?

Tumor stabilization?

Imaging?

Radionuclide delivery?

6. WHAT SYSTEMS COULD BE OVER-SUPPRESSED?

insulin?
glucagon?
bile?
pancreatic enzymes?
thyroid signaling?
cardiac conduction?

7. WHAT WOULD DEFINE SUCCESS?

Not:

“THE SOMATOSTATIN ANALOG LOWERED A HORMONE.”

But:

THE PATHOLOGICAL SECRETORY OR RECEPTOR-DRIVEN PHENOTYPE IMPROVED, THE TARGET HORMONE OR TUMOR OUTCOME MOVED IN THE DESIRED DIRECTION, AND NORMAL PANCREATIC, BILIARY, DIGESTIVE, GLYCEMIC, THYROID, AND CARDIOVASCULAR FUNCTION REMAINED ACCEPTABLE.

KEY TAKEAWAYS

Somatostatin is one of the body's major inhibitory peptide systems.

It exists primarily as SST-14 and SST-28.

Both forms activate five somatostatin receptors - SSTR1 through SSTR5.

All five receptors are Gi/o-coupled GPCRs whose canonical signaling reduces cAMP and calcium-dependent secretion.

That makes somatostatin a broad endocrine, exocrine, and neuronal brake.

At the pituitary it is especially important for suppressing GH through SSTR2 and SSTR5.

This is the inhibitory counterpart to GHRH and ghrelin.

The GH pulse therefore emerges from the balance of stimulation and inhibition rather than from a single releasing hormone.

Somatostatin also functions as a local pancreatic paracrine signal.

Delta cells release somatostatin, which suppresses both insulin and glucagon from neighboring beta and alpha cells.

This explains why somatostatin analogs can produce complex glucose effects.

They may suppress two hormones that normally oppose one another.

Somatostatin also suppresses multiple GI hormones and digestive secretions, including gastrin, secretin, VIP, motilin, and pancreatic output.

That broad antisecretory biology creates therapeutic value in hypersecretory diseases but also creates predictable risks such as steatorrhea, malabsorption, and biliary dysfunction when the system is over-suppressed.

Native somatostatin is clinically limited by an extremely short plasma half-life of roughly one to three minutes.

Synthetic analogs solved that pharmacokinetic problem.

Octreotide, lanreotide, and pasireotide extend exposure and alter receptor selectivity.

Octreotide is FDA approved for acromegaly and symptomatic treatment of metastatic carcinoid syndrome and VIPoma.

Pasireotide, with its stronger SSTR5 profile, is FDA approved for selected adults with Cushing disease.

That receptor difference is clinically important because SSTR5 also participates strongly in pancreatic insulin secretion.

Therefore pasireotide's pituitary efficacy comes with a greater tendency toward hyperglycemia.

This is one of the clearest examples of receptor selectivity creating both benefit and risk.

Somatostatin receptor biology also transformed neuroendocrine-tumor medicine.

Well-differentiated neuroendocrine tumors often overexpress SSTR2.

That receptor can be targeted three different ways:

FOR HORMONE SUPPRESSION.

FOR IMAGING.

FOR RADIONUCLIDE THERAPY.

This is the essence of somatostatin-receptor theranostics.

The receptor becomes a molecular address.

A radiolabeled ligand can reveal where the tumor is.

A therapeutic radioligand can deliver radiation to the same receptor-positive cells.

That makes somatostatin biology much more than endocrine suppression.

It is also a platform for precision molecular targeting.

- The best question is therefore not “what does somatostatin inhibit?”

Almost everything.

The better question is:

“WHICH secretory pathway is pathologically excessive, which SSTR subtype controls it, does the disease tissue express that receptor, what normal tissues share it, and can we suppress the pathological signal without suppressing too much normal physiology?”

THE BOTTOM LINE

Somatostatin is the perfect peptide to follow:

GHRH

and:

GHRELIN.

Because those two peptides teach:

HOW THE BODY TURNS GH ON.

Somatostatin teaches:

HOW THE BODY TURNS IT OFF.

But that is only the beginning.

The hypothalamus says:

STOP GH.

The pancreatic delta cell says:

SLOW INSULIN AND GLUCAGON.

The stomach says:

SLOW GASTRIN.

The intestine says:

SLOW SECRETORY OUTPUT.

The pancreas says:

SLOW EXOCRINE RELEASE.

The nervous system says:

REDUCE EXCITABILITY.

Again and again:

THE SAME BIOLOGICAL THEME APPEARS.

Restraint.

And restraint is not:

BAD PHYSIOLOGY.

It is what prevents:

OVERRESPONSE.

Then medicine takes this natural brake and engineers it.

Native somatostatin lasts:

ONLY MINUTES.

So we create:

OCTREOTIDE.

Longer lasting.

More useful.

Strong SSTR2 activity.

Now we can suppress:

GH

in acromegaly.

We can suppress:

VIP

in VIPoma.

We can suppress:

CARCINOID SECRETORY SYNDROMES.

Then we change the receptor profile.

We create:

PASIREOTIDE.

More SSTR5 activity.

Now ACTH-producing pituitary tumors become:

A DIFFERENT TARGET.

But beta cells also use SSTR5.

So:

INSULIN FALLS.

Glucose rises.

That is not random.

It is:

MECHANISM.

Then we take the system even further.

A neuroendocrine tumor expresses:

SSTR2.

So we attach a radiotracer.

The tumor lights up.

Then we attach:

A THERAPEUTIC RADIONUCLIDE.

Now the receptor becomes:

A DELIVERY ADDRESS.

At that point:

somatostatin biology has evolved from:

HYPOTHALAMIC PEPTIDE

to:

DRUG TARGET

to:

IMAGING TARGET

to:

TARGETED RADIOTHERAPY PLATFORM.

That is one of the most sophisticated examples of what peptide medicine can become.

And it reinforces a central Praxis principle:

THE GOAL IS NEVER “MORE SIGNAL” OR “LESS SIGNAL.”

The goal is:

THE RIGHT SIGNAL FOR THE PHYSIOLOGICAL STATE.

GH deficiency?

Do not activate the brake.

Acromegaly?

The brake may be exactly what is needed.

Secretory NET?

Suppress the pathological output.

SSTR2-positive tumor?

Use the receptor as a target.

Poor pancreatic function?

Be cautious about adding more inhibition.

Again:

THE PEPTIDE DOES NOT HAVE A MORAL DIRECTION.

The pathology determines whether:

AGONISM

or:

LESS SIGNALING

is desirable.

So the Praxis question becomes:

“WHAT secretory or proliferative signal is actually excessive, which somatostatin-receptor subtype controls that signal, is the receptor present at sufficient density in the pathological tissue, what normal endocrine or digestive physiology will be suppressed at the same time, and does the resulting biochemical, symptomatic, imaging, or tumor response justify the physiological cost of activating the body's inhibitory system?”

That is the difference between:

CALLING SOMATOSTATIN THE GH-INHIBITING HORMONE

and:

UNDERSTANDING A MULTIRECEPTOR ANTISECRETORY AND THERANOSTIC PLATFORM.

FINAL RECALL

IDENTIFY	TARGET	BALANCE
Name the excessive signal and relevant SSTR subtype	Confirm receptor phenotype before receptor-directed therapy	Measure target control and normal-system suppression together

STOP MEMORIZING PEPTIDES. START UNDERSTANDING THE SYSTEM.

Praxis Peptide Institute provides educational information and is not a substitute for individualized medical diagnosis or treatment. Somatostatin is an endogenous inhibitory peptide system acting through five receptor subtypes, SSTR1-SSTR5, to suppress endocrine, exocrine, neuronal, and secretory signaling. Native somatostatin and synthetic analogs should not be treated as interchangeable because analogs differ substantially in receptor selectivity, pharmacokinetics, clinical indications, and metabolic effects. Receptor-targeted treatment should therefore be matched to the pathological secretory pathway and receptor phenotype while monitoring normal pancreatic, biliary, gastrointestinal, pituitary, metabolic, and cardiovascular systems that share the same receptors.